Brazil Approves New Antiblindness Treatment

Eyetech Pharmaceuticals announced yesterday approval of Macugen in Brazil for the Treatment of Neovascular Age-Related Macular Degeneration.

The therapy is being presented as the first treatment that helps preserve vision in all subtypes of neovascular AMD by slowing vision loss.


The approval for Macugen was granted by Brazil’s National Health Surveillance Agency (Agência Nacional de Vigilância Sanitária).


The therapy was approved in the United States in December 2004 and in Canada in May 2005.  Eyetech and Pfizer Inc co-promote Macugen in the U.S. 


Eyetech has granted Pfizer the exclusive rights to commercialize Macugen in countries outside the U.S., including Brazil, pursuant to a royalty-bearing licensing agreement.


Macugen is the first in a new class of ophthalmic drugs to specifically target vascular endothelial growth factor (VEGF), a protein that acts as a signal in triggering the abnormal blood vessel growth and leakage that is the hallmark of neovascular AMD.


Macugen specifically binds to VEGF 165, a protein that plays a critical role in angiogenesis (the formation of new blood vessels) and increased permeability (leakage from blood vessels), two of the primary pathological processes thought to be responsible for the vision loss associated with neovascular AMD.  Thus, Macugen helps preserve vision by slowing vision loss.


Neovascular AMD is the leading cause of irreversible severe vision loss in patients older than 60 years of age in developed countries.  More than 500,000 people worldwide lose their sight annually from the disease. 


In Brazil, nearly 7 million people live with some form of AMD and more than 135,000 new cases are reported each year, with the incidence likely to increase significantly with a growing aging population.


Macugen is administered in a 0.3 mg dose once every six weeks by intravitreal injection.  It is expected to be available in the Brazilian market later this year.  Macugen has also been filed for approval in the European Union, Australia and Switzerland.


About Macugen


Macugen is indicated in the United States for the treatment of neovascular age-related macular degeneration, and in Canada for subfoveal choroidal neovascularization (CNV) secondary to neovascular AMD. 


Macugen is a pegylated anti-VEGF aptamer, which binds to vascular endothelial growth factor (VEGF). VEGF is a protein that plays a critical role in angiogenesis (the formation of new blood vessels) and increased permeability (leakage from blood vessels), two of the pathological processes that contribute to the vision loss associated with neovascular AMD.


Safety Information


Macugen is contraindicated in patients with ocular or periocular infections.


Intravitreal injections including those with Macugen have been associated with endophthalmitis.  Proper aseptic injection technique – which includes use of sterile gloves, a sterile drape, and a sterile eyelid speculum (or equivalent) – should always be utilized when administering Macugen. 


In addition, patients should be monitored during the week following the injection to permit early treatment, should an infection occur.


Increases in intraocular pressure (IOP) have been seen within 30 minutes of injection with Macugen. Therefore, IOP as well as the perfusion of the optic nerve head should be monitored and managed appropriately.


Serious adverse events related to the injection procedure occurring in less than 1% of intravitreal injections included endophthalmitis, retinal detachment, and iatrogenic traumatic cataract.


Most frequently reported adverse events in patients treated for up to 2 years were anterior chamber inflammation, blurred vision, cataract, conjunctival hemorrhage, corneal edema, eye discharge, eye irritation, eye pain, hypertension, increased IOP, ocular discomfort, punctate keratitis, reduced visual acuity, visual disturbance, vitreous floaters, and vitreous opacities.  These events occurred in approximately 10% to 40% of patients.


Eyetech Pharmaceuticals, Inc. is a biopharmaceutical company that specializes in the development and commercialization of novel therapeutics to treat diseases of the eye. 


Eyetech’s initial focus is on diseases affecting the back of the eye. Eyetech is commercializing and further developing Macugen (pegaptanib sodium injection) with Pfizer Inc for the treatment of neovascular AMD.  Macugen is also being studied for other indications including diabetic macular edema and retinal vein occlusion.


Eyetech Pharmaceuticals, Inc. – www.eyetk.com


Macugen – www.macugen.com


PRNewswire

Tags:

  • Show Comments (3)

  • LUIZ EUFRASIO RIBEIRO FILHO

    MACUGEN NO TRATAMENTO DA DEGENERAÀƒ‡AO MACULAR RELACIONADO A IDADE
    SOU OFTALMOLGISTA EM SÀƒƒO LUIS DO MARANHÀƒƒO=BRASIL. E GOSTARIA DE UTILIZAR O MACUGEN EM PACIENTES COM DEGENERAÀƒ‡AO MACULAR RELACIONADO A IDADE. QUERO TER AS INFORMAÀƒ‡OES SOBRE O PRODUTO, TAIS COMO, PREÀƒ‡O, DOSAGEM INTRAVITREA, PERIODO DE APLICAÀƒ‡OES ,ETC…..E COMO POSSO ADQUIRÀƒÂ-LO.

  • Guest

    gabymax@free.fr
    Is MACUGEN TREATMENT AVAILABLE IN SWITZERLAND ?

  • Guest

    maculopatia humeda
    hola, vivo en uruguay necesito saber donde aplican macugen en america (brasil or argentina), donde consigo macugen, a cuanto se vende, mi madre tiene 72 a˱os y ha perdido un ojo.
    I LIVE IN URUGUAY I NEED TO KNOW WHERE APLLICAT MACUGEN IN SUD AMERICA (BRAZIL OR ARGENTINA) WHERE I CAN BUY, COSTELLE, PRICE, MY MOTHER 72 EARS OLD AND SHE CANT SEE
    PLEASE SEND lvalassi@antel.com.uy thanks

Your email address will not be published. Required fields are marked *

comment *

  • name *

  • email *

  • website *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Ads

You May Also Like

Brazil Survey Shows Bad Economy But Not-Too-Bad Personal Finances

The results of the 18th Consumer Expectations Survey were released yesterday by the Getúlio ...

Brazil Closer to Legalizing Abortion Up to 22nd Week of Pregnancy

A commission created in April to debate changes in the country’s abortion legislation decided ...

Portuguese Minister Denies Brazil’s Adman Tried to Pass as Presidential Advisor

The ex-minister of Public Works of Portugal, Antonio Mexia, now denies that Brazilian adman ...

Brazil to Map Invasive Aliens Such as Wild Boars and Snails

Brazil’s First Symposium on Exotic Species began Tuesday, October 4, and will run until ...

Brazilian Industry Grows for Third Month in a Row

Brazil’s industrial sector output rose for the third consecutive month in May, reports the ...

Brazil’s Light For All Served 375,000. There Are Another 625,000 In Line.

Since its implantation in 2003, the Light for All Program in Brazil has created ...

Brazil Asked to Vote Less Against Israel in the UN

Brazil and Israel concluded a formal agreement, on Sunday, May 29, that establishes principles ...

Brazil’s Paper and Pulp Maker Aracruz Grows with Asia Help

Aracruz Celulose began a plan for modernization of their unit in the city of ...

Montenegro Republic Buys 116-Seat Brazilian Jet

Brazilian aircraft manufacturer Embraer sold its first Embraer 195 jet to Montenegro Airlines, this ...

Forever Tunes

Producer Ricardo Cravo Alvim thinks that marchinhas resist because they were created with the ...